The dengue vaccine developed by the Butantan Institute is currently under review by Brazil's National Agency of Sanitary Surveillance (Anvisa). If approved, the Butantan-DV will be the first single-dose vaccine for dengue globally. Anvisa evaluates the safety and effectiveness of vaccines before they can be registered for use.
Clinical trials for this vaccine concluded in June 2024. Results show it is 79.6% effective against symptomatic dengue and 89% against severe cases. If it receives approval soon, Butantan plans to produce one million doses in 2025, with the expectation of increasing production to 60 million doses in 2026.
The vaccine is designed for individuals aged 2 to 60 years and requires only one injection. Future studies may also include older individuals. The Butantan Institute is also working on a vaccine for chikungunya, which has been approved in the United States and Europe, and is awaiting Anvisa's decision in Brazil.